Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Opening a business credit card is often framed as a way to separate expenses and earn basic rewards, but the real value can ...

FLOOD CONTROL composite image from INQUIRER FILE MANILA, Philippines — The floods came first. In Bulacan, Pampanga, and parts ...

We chose H&R Block as our best overall online tax service because of its transparent pricing, easy-to-use platform, and ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

A Detroit church on the brink found new life with new pastors who embrace inclusion, questions and transcendence.

Zohran Mamdani is now mayor of New York City, and the Left’s old ways of relating to elected officials won’t cut it. We need ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

The companies that survive will look less like pyramids and more like swarms: small, autonomous AI-first pods that move and ...